Reports and Briefs on Central Nervous System in Asia-Pacific

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Type Product title / description Pub Price
Report
Report

Treatment Algorithms: Schizophrenia – New antipsychotic launches underwhelm

Analysis of current treatment dynamics in schizophrenia. The report assesses patient diagnosis rates and uptake rates of approved treatments across the seven major markets using Datamonitor’s primary physician research of 140 psychiatrists.

Published By Datamonitor
15 May 2012 $7600
Buy
Report
Report

Treatment Algorithms: Postherpetic Neuralgia – Lyrica forms the cornerstone of treatment for postherpetic neuralgia

Analysis of the treatment dynamics in postherpetic neuralgia (PHN). Contains analyses of presentation, diagnosis and treatment rates, and prescribing trends across the seven major markets using Datamonitor’s primary research of 131 physicians.

Published By Datamonitor
13 Nov 2012 $7600
Buy
Report
Report

Treatment Algorithms: Multiple Sclerosis - Interferons remain the mainstay of multiple sclerosis treatment

Analysis of current treatment dynamics in multiple sclerosis. The report assesses the prescribing patterns, patient segmentation, and compliance rates across the seven major markets using Datamonitor’s primary physician research of 133 neurologists.

Published By Datamonitor
16 Mar 2012 $7600
Buy
Report
Report

Treatment Algorithms: Alzheimer's Disease – Off-label prescribing driven by dearth of treatment options

Analysis of current treatment dynamics in Alzheimer’s disease. The report assesses patient diagnosis rates and uptake rates of approved treatments across the seven major markets using Datamonitor’s primary physician research of 133 neurologists.

Published By Datamonitor
01 Mar 2012 $7600
Buy
Report
Report

The Orphan Drug Market Outlook to 2017

This report provides an analysis of the orphan drug market. It comprises brands that have gained US FDA orphan drug approval, as well as Phase III pipeline candidates that have gained an orphan drug designation from the FDA.

Published By Datamonitor
08 Jan 2013 $3500
Buy

Order this report by October 22nd 2010 and receive a 30% discount

To take advantage of this offer enter Promo Code TBI30 when prompted in the checkout

More information

Report
Report

Stakeholder Opinions: Traumatic Brain Injury - Hormonal therapy generates optimism

Analysis of traumatic brain injury epidemiology, unmet needs and pipeline treatments. Provides analysis of opportunities and threats facing developers of TBI treatments based on interviews with six key opinion leaders.

Published By Datamonitor
07 Apr 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness

This report assesses the current landscape of and future opportunities for therapeutic vaccines outside cancer, covering therapeutic vaccine approaches in cardiovascular and metabolic, CNS, autoimmune and infectious diseases.

Published By Datamonitor
17 Dec 2009 $3800
Buy
Report
Report

Stakeholder Opinions: Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market

Assessment of the potential impact of agents targeting nerve growth factor (NGF) for the treatment of pain. Includes analysis of the key market drivers and resistors for this new class based on interviews with key opinion leaders.

Published By Datamonitor
05 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential

Analysis of spinal cord injury epidemiology, unmet needs and pipeline treatments. Provides assessment of potential market value and analysis of opportunities and threats facing developers of SCI treatments based on interviews with key opinion leaders

Published By Datamonitor
05 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development

Comprehensive analysis of the gene therapy clinical pipeline across all geographic and therapeutic markets, with key opinion leader insights. Identification of drivers and inhibitors to the commercial success of gene therapy.

Published By Datamonitor
10 Dec 2009 $3800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.